Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy’s Path Cleared For Authorized Prilosec Launch

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - The 1.5 billion dollar Indian drug-maker Ranbaxy launched an authorized generic version of anti-ulcer drug omeprazole 40 mg in the U.S. as part of an agreement reached earlier with the gastric ulcer and Zollinger-Ellison syndrome treatment's innovator AstraZeneca
Advertisement

Related Content

Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
Ranbaxy Will Begin U.S. Sales Of Generic Nexium In 2014 Under Deal Ending Patent Litigation
Advertisement
UsernamePublicRestriction

Register

SC069143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel